Pharmacologic options for the control of peptic ulcer disease.
D000863:Antacids / Q000627:therapeutic use; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D001729:Bismuth / Q000627:therapeutic use; D002229:Carbenoxolone / Q000627:therapeutic use; D002927:Cimetidine / Q000627:therapeutic use; D004381:Duodenal Ulcer / Q000188:drug therapy; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D009853:Omeprazole; D010276:Parasympatholytics / Q000627:therapeutic use; D010437:Peptic Ulcer / Q000188:drug therapy*; D011465:Prostaglandins, Synthetic / Q000627:therapeutic use; D011899:Ranitidine / Q000627:therapeutic use; D012306:Risk; D013274:Stomach Neoplasms / Q000139:chemically induced; D013501:Surface-Active Agents / Q000627:therapeutic use
D000863:Antacids; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D006635:Histamine H2 Antagonists; D010276:Parasympatholytics; D011465:Prostaglandins, Synthetic; D013501:Surface-Active Agents; D002927:Cimetidine; D011899:Ranitidine; D009853:Omeprazole; D002229:Carbenoxolone; D001729:Bismuth